Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMvigor010: Adjuvant Atezolizumab in Muscle-Invasive Urothelial Carcinoma
NCT02450331Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2015
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of atezolizumab in urothelial carcinoma (UC), sponsored by Roche. Started Oct 2015; status: terminated.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02450331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450331.